<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780115</url>
  </required_header>
  <id_info>
    <org_study_id>199201-010</org_study_id>
    <nct_id>NCT02780115</nct_id>
  </id_info>
  <brief_title>A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia</brief_title>
  <official_title>A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy, and Pharmacokinetics of the Fixed Combination of AGN-199201 and AGN-190584 in Patients With Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety, efficacy and pharmacokinetics study of the fixed combination of AGN-199201&#xD;
      and AGN-190584 in participants with presbyopia (inability to focus on items close-up).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2016</start_date>
  <completion_date type="Actual">October 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weighted Average Change From Baseline in Uncorrected Near Visual Acuity (UNVA) Letters in the Nondominant Eye</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>UNVA is assessed without corrective lenses in the non-dominant eye. UNVA is measured using an eye chart and is reported as the number of lines read correctly. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of lines read correctly means that vision has improved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing One or More Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>up to 65 days</time_frame>
    <description>A Treatment Emergent Adverse Event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. An Adverse Drug Reaction was a harmful and unintended reaction that is incurred during routine administration or use of the drug, whose causal relationship with the drug cannot be excluded.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Vehicle Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vehicle dosed in both eyes administered once daily during office visits 1 through 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed combinations of AGN-199201 Dose A and AGN-190584 Dose A dosed in both eyes administered once daily during office visits 1 through 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed combinations of AGN-199201 Dose B and AGN-190584 Dose B dosed in both eyes administered once daily during office visits 1 through 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in both eyes administered once daily during office visits 1 through 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-199201 ophthalmic solution</intervention_name>
    <description>1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.</description>
    <arm_group_label>Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A</arm_group_label>
    <arm_group_label>Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B</arm_group_label>
    <arm_group_label>Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C</arm_group_label>
    <arm_group_label>Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-190584 ophthalmic solution</intervention_name>
    <description>1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.</description>
    <arm_group_label>Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A</arm_group_label>
    <arm_group_label>Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B</arm_group_label>
    <arm_group_label>Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C</arm_group_label>
    <arm_group_label>Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-199201 Vehicle</intervention_name>
    <description>Vehicle to AGN-199201</description>
    <arm_group_label>Cohort 1: Vehicle Control</arm_group_label>
    <arm_group_label>Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-190584 Vehicle</intervention_name>
    <description>Vehicle to AGN-190584</description>
    <arm_group_label>Cohort 1: Vehicle Control</arm_group_label>
    <arm_group_label>Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal vision at distance, either natural or post corneal laser refractive surgery,&#xD;
             with presbyopia in each eye and complaints of poor near vision that impacts activities&#xD;
             of daily living&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any topical ophthalmic medications, including artificial tears other than the&#xD;
             study medications during the study&#xD;
&#xD;
          -  Corneal abnormalities in either eye that interfere with visual acuity&#xD;
&#xD;
          -  History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery or&#xD;
             any intraocular surgery&#xD;
&#xD;
          -  Diagnosis of glaucoma or ocular hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haixia Liu</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Institute of California Medical Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sall Research Medical Center</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WCCT Global, LLC</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialty Eye Care Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lugene Eye Institute</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Eye and Laser Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolstan and Golberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedEye Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Eye Institute</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Sight</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Eye Center</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silverstein Eye Centers</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Care Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Eye Care</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James D. Branch</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devers Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; Christie and Associates, PC</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care, PA</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cataract and Glaucoma Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R and R Eye Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoopes Durrie Rivera Research, LLC</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <results_first_submitted>October 16, 2020</results_first_submitted>
  <results_first_submitted_qc>December 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2020</results_first_posted>
  <disposition_first_submitted>October 16, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>October 16, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 18, 2018</disposition_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02780115/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02780115/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Randomization and treatment assignment were based on a randomization scheme prepared by Allergan Biostatistics prior to the start of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Vehicle Control</title>
          <description>Vehicle dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: AGN-199201 Lower Dose and AGN-190584 Lower Dose</title>
          <description>Fixed combinations of AGN-199201 Lower Dose and AGN-190584 Lower Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: AGN-199201 Medium Dose and AGN-190584 Medium Dose</title>
          <description>Fixed combinations of AGN-199201 Medium Dose and AGN-190584 Medium Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4: AGN-199201 Higher Dose and AGN-190584 Higher Dose</title>
          <description>Fixed combinations of AGN-199201 Higher Dose and AGN-190584 Higher Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5: Vehicle, AGN-199201 Higher Dose and AGN-190584 Higher Dose</title>
          <description>Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Higher Dose and AGN-190584 Higher Dose dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population: All patients who received ≥ 1 administration of study treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Vehicle Control</title>
          <description>Vehicle dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: AGN-199201 Lower Dose and AGN-190584 Lower Dose</title>
          <description>Fixed combinations of AGN-199201 Lower Dose and AGN-190584 Lower Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3: AGN-199201 Medium Dose and AGN-190584 Medium Dose</title>
          <description>Fixed combinations of AGN-199201 Medium Dose and AGN-190584 Medium Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4: AGN-199201 Higher Dose and AGN-190584 Higher Dose</title>
          <description>Fixed combinations of AGN-199201 Higher Dose and AGN-190584 Higher Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5: Vehicle, AGN-199201 Higher Dose and AGN-190584 Higher Dose</title>
          <description>Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Higher Dose and AGN-190584 Higher Dose dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="32"/>
            <count group_id="B5" value="31"/>
            <count group_id="B6" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" spread="3.9"/>
                    <measurement group_id="B2" value="49.4" spread="2.7"/>
                    <measurement group_id="B3" value="47.9" spread="3.9"/>
                    <measurement group_id="B4" value="49.2" spread="3.8"/>
                    <measurement group_id="B5" value="48.1" spread="3.4"/>
                    <measurement group_id="B6" value="48.6" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline UNVA severity</title>
          <description>Baseline UNVA measured visual acuity using Snellen Scores. Worse &quot;severity&quot; meant poorer visual acuity as measured by baseline UNVA (uncorrected near visual acuity). This graded measure was used to stratify participants into two groups: UNVA at baseline (≤ 20/80 and &gt; 20/80).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≤ 20/80</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 20/80</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weighted Average Change From Baseline in Uncorrected Near Visual Acuity (UNVA) Letters in the Nondominant Eye</title>
        <description>UNVA is assessed without corrective lenses in the non-dominant eye. UNVA is measured using an eye chart and is reported as the number of lines read correctly. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of lines read correctly means that vision has improved.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Modified Intent-to-Treat (mITT) population: all randomized patients who were randomized with a baseline and at least 1 post baseline assessment of mesopic, high contrast, UNVA.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Vehicle Control</title>
            <description>Vehicle dosed in both eyes administered once daily during office visits 1 through 5.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: AGN-199201 Lower Dose and AGN-190584 Lower Dose</title>
            <description>Fixed combinations of AGN-199201 Lower Dose and AGN-190584 Lower Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: AGN-199201 Medium Dose and AGN-190584 Medium Dose</title>
            <description>Fixed combinations of AGN-199201 Medium Dose and AGN-190584 Medium Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: AGN-199201 Higher Dose and AGN-190584 Higher Dose</title>
            <description>Fixed combinations of AGN-199201 Higher Dose and AGN-190584 Higher Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Vehicle, AGN-199201 Higher Dose and AGN-190584 Higher Dose</title>
            <description>Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Higher Dose and AGN-190584 Higher Dose dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Average Change From Baseline in Uncorrected Near Visual Acuity (UNVA) Letters in the Nondominant Eye</title>
          <description>UNVA is assessed without corrective lenses in the non-dominant eye. UNVA is measured using an eye chart and is reported as the number of lines read correctly. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of lines read correctly means that vision has improved.</description>
          <population>Modified Intent-to-Treat (mITT) population: all randomized patients who were randomized with a baseline and at least 1 post baseline assessment of mesopic, high contrast, UNVA.</population>
          <units>letters correctly read</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="1.03"/>
                    <measurement group_id="O2" value="4.96" spread="1.00"/>
                    <measurement group_id="O3" value="7.77" spread="1.00"/>
                    <measurement group_id="O4" value="7.54" spread="0.97"/>
                    <measurement group_id="O5" value="7.81" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1663</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Diff</param_type>
            <param_value>1.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>4.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Diff</param_type>
            <param_value>4.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.98</ci_lower_limit>
            <ci_upper_limit>7.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Diff</param_type>
            <param_value>4.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>7.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Diff</param_type>
            <param_value>4.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.03</ci_lower_limit>
            <ci_upper_limit>7.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing One or More Treatment Emergent Adverse Events (TEAEs)</title>
        <description>A Treatment Emergent Adverse Event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. An Adverse Drug Reaction was a harmful and unintended reaction that is incurred during routine administration or use of the drug, whose causal relationship with the drug cannot be excluded.</description>
        <time_frame>up to 65 days</time_frame>
        <population>Modified Intent-to-Treat (mITT) population: all randomized patients who were randomized with a baseline and at least 1 post baseline assessment of mesopic, high contrast, UNVA.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Vehicle Control</title>
            <description>Vehicle dosed in both eyes administered once daily during office visits 1 through 5.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: AGN-199201 Lower Dose and AGN-190584 Lower Dose</title>
            <description>Fixed combinations of AGN-199201 Lower Dose and AGN-190584 Lower Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: AGN-199201 Medium Dose and AGN-190584 Medium Dose</title>
            <description>Fixed combinations of AGN-199201 Medium Dose and AGN-190584 Medium Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: AGN-199201 Higher Dose and AGN-190584 Higher Dose</title>
            <description>Fixed combinations of AGN-199201 Higher Dose and AGN-190584 Higher Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Vehicle, AGN-199201 Higher Dose and AGN-190584 Higher Dose</title>
            <description>Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Higher Dose and AGN-190584 Higher Dose dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing One or More Treatment Emergent Adverse Events (TEAEs)</title>
          <description>A Treatment Emergent Adverse Event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. An Adverse Drug Reaction was a harmful and unintended reaction that is incurred during routine administration or use of the drug, whose causal relationship with the drug cannot be excluded.</description>
          <population>Modified Intent-to-Treat (mITT) population: all randomized patients who were randomized with a baseline and at least 1 post baseline assessment of mesopic, high contrast, UNVA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected for up to 65 days.</time_frame>
      <desc>Safety population: All patients who received ≥ 1 administration of study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Vehicle Control</title>
          <description>Vehicle dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: AGN-199201 Lower Dose and AGN-190584 Lower Dose</title>
          <description>Fixed combinations of AGN-199201 Lower Dose and AGN-190584 Lower Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3: AGN-199201 Medium Dose and AGN-190584 Medium Dose</title>
          <description>Fixed combinations of AGN-199201 Medium Dose and AGN-190584 Medium Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4: AGN-199201 Higher Dose and AGN-190584 Higher Dose</title>
          <description>Fixed combinations of AGN-199201 Higher Dose and AGN-190584 Higher Dose dosed in both eyes administered once daily during office visits 1 through 5.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5: Vehicle, AGN-199201 Higher Dose and AGN-190584 Higher Dose</title>
          <description>Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Higher Dose and AGN-190584 Higher Dose dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Instillation site foreign body sensation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Instillation site lacrimation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>IR-CTRegistration@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

